On November 9, 2021 Wugen, Inc., a clinical-stage biotechnology company developing a pipeline of off-the-shelf memory natural killer (NK) cell therapies to treat a broad range of hematological and solid tumor malignancies, reported it will present new data highlighting the preclinical development of Wugen’s lead product WU-NK-101 at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper)’s (SITC) (Free SITC Whitepaper) 36th Annual Meeting (Press release, Wugen, NOV 9, 2021, View Source [SID1234594939]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The data highlight Wugen’s proprietary large-scale feeder-cell free manufacturing process and demonstrate WU-NK-101’s robust memory phenotype and enhanced anti-tumor activity. Further, the data demonstrate that in combination with monoclonal antibodies, WU-NK-101 exhibits enhanced efficacy against solid tumor cell lines. In summary, the data provide support for development of WU-NK-101 as an off-the-shelf cell therapy for the treatment of acute myelogenous leukemia (AML) and solid tumors.

The details of Wugen’s presentation at SITC (Free SITC Whitepaper) are as follows:

Title: Development of WU-NK-101, a feeder cell-free expanded allogeneic memory NK cell product with potent anti-tumor activity
Presenting Author: Mary E. Mathyer, Ph.D.
Abstract Number: 188
Abstracts will be available Tuesday, November 9, 2021, at 8:00 a.m. ET
Additional meeting information can be found on the SITC (Free SITC Whitepaper) website at:
View Source

On November 9, 2021 Australian clinical-stage drug development company Noxopharm (ASX:NOX) reported its DARRT-2 Phase 2 clinical trial has commenced with patient enrollment in the U.S (Press release, Noxopharm, NOV 9, 2021, View Source [SID1234594938]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

DARRT (Direct and Abscopal Response to Radiotherapy) is an experimental immunotherapy cancer treatment based on the concept of Veyonda combining with a well-tolerated, low dosage of external beam radiotherapy to trigger an immune response — known as an abscopal response — which may lead to the resolution of tumors.

DARRT treatment has the potential to revolutionize cancer treatment by achieving cancer reduction without many of the unwanted side effects, cost limitations, and logistical challenges associated with other immunotherapies.

Since low dose radiotherapy is a common form of cancer therapy, the therapeutic and commercial opportunities of adding Veyonda to transform symptomatic relief into a meaningful tumor response are substantial. Noxopharm is confident of securing the value of this opportunity by patents, starting with the allowance of claims by the U.S. Patent Office.

The inaugural sites are the Beverly Hills Cancer Center and the MD Anderson Cancer Center, with remaining sites in North America, Europe, and Australia.

Noxopharm Chief Medical Officer, Dr. Gisela Mautner, said, "The participation of institutions with prestigious radiation and medical oncologists is testament to the potential of the DARRT-treatment."

On November 9, 2021 RenovoRx, Inc. (Nasdaq: RNXT), a biopharmaceutical company and innovator in targeted cancer therapy, reported its novel therapy platform, RenovoTAMPTM (RenovoRx Trans-Arterial Micro-Perfusion), will be highlighted during a presentation by expert panelist, Dr. Ripal Gandhi, at the Miami Cancer Institute’s New Advances in the Management of Pancreatic Cancer CME course this evening (Press release, Renovorx, NOV 9, 2021, View Source [SID1234594937]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. Gandhi, a Principal Investigator in RenovoRx’s ongoing Phase 3 TIGeR-PaC study, and Professor of Interventional Radiology at the Miami Cancer Institute and Miami Cardiac and Vascular Institute, Florida International University Herbert Wertheim College of Medicine, will describe the results from initial clinical studies of RenovoTAMP used in combination with radiation therapy and its benefits when managing patients with stage 3 locally advanced pancreatic cancer (LAPC). He will also review the key stages of the TIGeR-PaC protocol which uses RenovoTAMP for the intra-arterial delivery of gemcitabine, an approved chemotherapeutic agent, to treat unresectable LAPC. To highlight a critical difference between intravenous (IV) and intra-arterial (IA) chemotherapy, Dr. Gandhi will present pharmacokinetic data, or data describing the drug absorption/distribution/metabolism/excretion of gemcitabine from five patients in the Phase 3 TIGeR-PaC study that received intra-arterial gemcitabine. The data demonstrates an approximately two-thirds reduction in systemic gemcitabine when compared to systemic levels in patients traditionally receiving IV infusion of gemcitabine.

"This innovative therapy platform is enabling the targeted treatment of inoperable LAPC with decreased side effects typical of systemic chemotherapy, while shifting the focus to what is most important to our patients: improving quality of life and allowing them to spend more time with their family and loved ones," said Dr. Gandhi. "RenovoTAMP, when used in combination with radiation therapy, is designed to reduce arterial microvasculature, thereby minimizing leakage during drug delivery and enhancing drug delivery directly to the tumor."

A copy and recording of Dr. Gandhi’s presentation, titled "Potential Future Innovative Strategy for Pancreatic Cancer: Intra-Arterial Chemotherapy," will be available on RenovoRx’s website at View Source

About the Phase 3 TIGeR-PaC Clinical Trial

The TIGeR-PaC clinical trial is a randomized multi-center study using the RenovoTAMPTM platform to evaluate RenovoRx’s first product candidate, RenovoGemTM to treat unresectable LAPC through the intra-arterial delivery of gemcitabine, an approved chemotherapeutic agent. TIGeR-PaC is currently enrolling locally advanced, unresectable pancreatic cancer patients. To learn more about the study and the participating clinical trial sites, visit View Source

On November 9, 2021 NOXXON Pharma N.V. (Euronext Growth Paris: ALNOX), a biotechnology company focused on improving cancer treatments by targeting the tumor microenvironment (TME), reported that Aram Mangasarian, Chief Executive Officer of NOXXON, will present at Investir Day 2021, at the Palais Brongniart in Paris on November 23, 2021 and will be available for virtual meetings with participants from November 15 to 23, 2021 (Press release, NOXXON, NOV 9, 2021, View Source [SID1234594936]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details of the presentation are as follow:

Title: "NOXXON Pharma: a specialist in the development of new cancer treatments targeting the tumoral microenvironment" – the presentation will be held in French
Time: Tuesday, November 23, 2021 at 09:35 – 09:55 am CET, at the Palais Brongniart in Paris, France
To register, please click here
To request a one-on-one meeting with Aram Mangasarian, please contact [email protected].

On November 9, 2021 Biognosys, a leader in proteomics solutions for drug discovery and development, reported the launch of its next-generation blood biomarker discovery solution, which will be offered as a contract research service (Press release, Biognosys, NOV 9, 2021, View Source [SID1234594935]). The service is designed to help researchers decipher the complexity of the blood proteome and unlock unbiased discoveries for pharma and diagnostics development and precision medicine.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The launch will feature a series of events and resources that detail the science and technology behind the new solution, as well as its applications:

Launch webinar on November 9, entitled: "Plasma Proteomics: The Next Frontier of Biomarker Discovery in the Precision Medicine Era."
Presentation and exhibition at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) Annual Meeting on November 12-14 in Washington, D.C.
The new service offers unprecedented depth, quantitative precision, and throughput for discovery research. The solution will search the complete plasma proteome to quantify up to 3,000 of the most relevant proteins and measure tens of thousands of peptide-level datapoints to provide a deep understanding of key disease pathways.

The solution can be applied across all biological species and to any other biofluid, such as cerebrospinal fluid or urine. In addition to the biofluid biomarker discovery service, an improved tissue biomarker discovery service is available, offering an industry-leading depth of 10,000 proteins.

Both solutions are based on Biognosys’ proprietary, patented Hyper Reaction Monitoring (HRM) technology and its optimized Liquid Chromatography – Mass Spectrometry (LC-MS) workflow. The clinical transferability of this technology allows quick transition from early stage discovery to specific, targeted panels that can be applied in a regulated setting.

Kanna Palaniappan, PhD, Staff Scientist at Freenome, a company that develops blood tests for early cancer detection, powered by a multi-omics platform, testifies: "We have used Biognosys’ services for a number of biomarker discovery studies focused on improving cancer detection, taking advantage of their constantly improving platform, and their ability to run large-scale studies while maintaining high data quality. We have had a valuable and productive relationship and we look forward to future collaborations."

Kristina Beeler, PhD, Chief Business Officer of Biognosys, comments: "We are thrilled to offer customers our innovative, next-generation biomarker discovery solution and enable them to gain biological insights beyond what pre-defined panels can provide. By diving deep into the plasma proteome with an unbiased view, we profile the proteins that are of highest relevance to our customer’s disease areas of focus. This is what we call true discovery."

Lukas Reiter, PhD, Chief Technology Officer of Biognosys states: "Mass spectrometry-based proteomics is the ideal tool to explore the blood proteome in an unbiased manner. Our continuous R&D improvements have enabled us to reach an unprecedented depth to quantify the very low abundant protein ranges that are of highest biological significance, while ensuring high scalability for clinical research."